Biocartis Announces Nine Idylla™ Studies Published at AMP 2022 Annual Meeting

15Nov

Biocartis Announces Nine Idylla™ Studies Published at AMP 2022 Annual Meeting

Last updated: 21st March, 2024

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.

Among the studies published, four studies on the Idylla™ GeneFusion Assay highlighted the strengths of Idylla™ testing including high accuracy, ease-of-use and rapid time-to-results.

Furthermore, one study performed with the new SeptiCyte RAPID^® EDTA blood-compatible cartridges⁴ on the Idylla™ platform, developed in collaboration with Immunexpress, concluded that the addition of the widely used EDTA blood tube as a validated sample type has the potential to greatly enhance the clinical utility of this new near-patient sepsis diagnostic.

The other studies related to the use of the Idylla™ EGFR Assay, the Idylla™ MSI Assay, and the Idylla™ NRAS-BRAF Assay.

These studies highlight the benefit of Idylla™ testing versus more complex and time-consuming technologies. With Idylla™, the time-to-result of diagnostic testing is decreased, indicating the suitability of Idylla™ testing for rapid molecular testing.

Page	Abstract ID	Title
53	ID007	Multi-Site Validation of EDTA Blood as a Sample Type for SeptiCyte RAPID CE-IVD, a Near-Patient Diagnostic Test for Sepsis on the Biocartis Idylla System
79	I012	Evaluation of RET Fusion Identification by the Idylla GeneFusion Assay
90	ST006	Clinical Validation of an Automated Gene Fusion Assay for Non-Small Cell Lung Carcinoma
90	ST008	Development and Validation of an Ultra-Rapid Assay for Detection of NTRK1/2/3 Fusions
92	ST013	Validation of Idylla EGFR Assay for Rapid Detection of EGFR Mutations in Patients’ FFPE Tissues
94	ST016	Performance of MSI Testing by the Automated Rapid Idylla Assay in Comparison with the Promega Assay in MMR-Deficient Endometrial Carcinomas
95	ST019	BioCartis Idylla Testing for EGFR Mutations in Lung Adenocarcinoma Reveals Low Clinical Sensitivity for Detecting Exon 20 Insertion Alterations
100	ST034	Rapid Assessment of Kinase Gene Fusions Using the Idylla GeneFusion Assay in Lung Adenocarcinoma
103	ST041	Idylla BRAF and NRAS